July 2, 2014, Vol 312, No. 1, Pages 1-99

In This Issue of JAMA

Highlights

Abstract Full Text

free access has audio

JAMA. 2014;312(1):1-3. doi:10.1001/jama.2013.279585

Audio Editors' Summary: Erythropoietin for TBI, HSCT for severe sickle cell diseaes, everolimus for hepatocellular carcinoma, and more.

Original Investigation

Caring for the Critically Ill Patient

Effect of Erythropoietin and Transfusion Threshold on Neurological Recovery After Traumatic Brain Injury: A Randomized Clinical Trial

Claudia S. Robertson, MD; H. Julia Hannay, PhD; José-Miguel Yamal, PhD; et al.

Abstract Full Text

free access has audio

JAMA. 2014;312(1):36-47. doi:10.1001/jama.2014.6490

Robertson and coauthors and the Epo Severe TBI Trial Investigators report the results of a randomized clinical trial on the effect of erythropoietin administration and transfusion threshold on neurological recovery after traumatic brain injury.

Audio Author Interview: of Effect of Erythropoietin and Transfusion Threshold on Neurological Recovery After Traumatic Brain Injury: A Randomized Clinical Trial

Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Phenotype

Matthew M. Hsieh, MD; Courtney D. Fitzhugh, MD; R. Patrick Weitzel, PhD; et al.

Abstract Full Text

free access has multimedia has audio

JAMA. 2014;312(1):48-56. doi:10.1001/jama.2014.7192

In a trial involving 30 adult patients with sickle cell phenotype with or without thalassemia, Hsieh and coauthors report that after undergoing nonmyeloablative allogeneic hematopoietic stem cell transplantation from human leukocyte antigen–matched siblings, 26 patients achieved long-term engraftment.

Audio Author Interview: Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Phenotype

Editorial
Reconsideration of Age as a Contraindication for Curative Therapy of Sickle Cell Disease
Allison A. King, MD, MPH; John F. DiPersio, MD, PhD

Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib: The EVOLVE-1 Randomized Clinical Trial

Andrew X. Zhu, MD, PhD; Masatoshi Kudo, MD, PhD; Eric Assenat, MD, PhD; et al.

Abstract Full Text

free access

JAMA. 2014;312(1):57-67. doi:10.1001/jama.2014.7189

With the first Everolimus for Liver Cancer Evaluation (EVOLVE-1) study, Zhu and coauthors investigated the efficacy of everolimus in patients with advanced hepatocellular carcinoma for whom sorafenib treatment failed. This randomized, double-blind, phase 3 study was conducted among 546 adults with Barcelona Clinic Liver Cancer stage B or C hepatocellular carcinoma and Child-Pugh A liver function.

Use of Whole-Exome Sequencing to Determine the Genetic Basis of Multiple Mitochondrial Respiratory Chain Complex Deficiencies

Robert W. Taylor, PhD, FRCPath; Angela Pyle, PhD; Helen Griffin, PhD; et al.

Abstract Full Text

free access

JAMA. 2014;312(1):68-77. doi:10.1001/jama.2014.7184

To determine the molecular basis of multiple respiratory chain complex deficiencies, Taylor and coauthors used a whole-exome sequencing approach in 53 patients with biochemical evidence of multiple respiratory chain complex defects but no primary pathogenic mitochondrial DNA mutation.

Research Letter

Hospital Deaths in Patients With Sepsis From 2 Independent Cohorts

Vincent Liu, MD, MS; Gabriel J. Escobar, MD; John D. Greene, MA; et al.

Abstract Full Text

free access

JAMA. 2014;312(1):90-92. doi:10.1001/jama.2014.5804

Viewpoint

Drugs for Macular Degeneration, Price Discrimination, and Medicare’s Responsibility Not to Overpay

Jonathan Silver, MD, MBA

Abstract Full Text

JAMA. 2014;312(1):23-24. doi:10.1001/jama.2014.6672

Transcatheter Aortic Valve Replacement: Flattening the Cost Curve

Arthur M. Feldman, MD, PhD; Verdi J. DiSesa, MD, MBA

Abstract Full Text

JAMA. 2014;312(1):25-26. doi:10.1001/jama.2014.4606

The Global Health Security Agenda in an Age of Biosecurity

Lawrence O. Gostin, JD; Alexandra Phelan, LLM, BBiomedSc/LLB(Hons)

Abstract Full Text

JAMA. 2014;312(1):27-28. doi:10.1001/jama.2014.4843

Hospital Consolidation, Competition, and Quality: Is Bigger Necessarily Better?

Thomas C. Tsai, MD, MPH; Ashish K. Jha, MD, MPH

Abstract Full Text

has audio

JAMA. 2014;312(1):29-30. doi:10.1001/jama.2014.4692

Author Reading: JAMA: 2014-07-01, Vol. 312, No. 1, Author Reading

A Piece of My Mind

Nominal Competence in Health Care

Gautham Suresh, MD

Abstract Full Text

JAMA. 2014;312(1):31-32. doi:10.1001/jama.2014.5579

Editorial

Reconsideration of Age as a Contraindication for Curative Therapy of Sickle Cell Disease

Allison A. King, MD, MPH; John F. DiPersio, MD, PhD

Abstract Full Text

JAMA. 2014;312(1):33-34. doi:10.1001/jama.2014.7193

Introducing the JAMA Guide to Statistics and Methods

Edward H. Livingston, MD

Abstract Full Text

free access

JAMA. 2014;312(1):35. doi:10.1001/jama.2014.7991

The Rational Clinical Examination

Does This Patient Have Generalized Anxiety or Panic Disorder?The Rational Clinical Examination Systematic Review

Nathaniel R. Herr, PhD; John W. Williams Jr, MD, MHSc; Sophiya Benjamin, MD; et al.

Abstract Full Text

JAMA. 2014;312(1):78-84. doi:10.1001/jama.2014.5950

In this The Rational Clinical Examination article, Herr and colleagues discuss results of a literature search to evaluate self-report screening instruments to identify generalized anxiety disorder and panic disorder.

JAMA Guide to Statistics and Methods

The Intention-to-Treat Principle: How to Assess the True Effect of Choosing a Medical Treatment

Michelle A. Detry, PhD; Roger J. Lewis, MD, PhD

Abstract Full Text

has audio

JAMA. 2014;312(1):85-86. doi:10.1001/jama.2014.7523

Audio: JAMA Guide to Statistics and Methods

From the JAMA Network

Sunscreen Counseling by US Physicians

Daniel G. Federman, MD; Robert S. Kirsner, MD, PhD; John Concato, MD

Abstract Full Text

JAMA. 2014;312(1):87-88. doi:10.1001/jama.2014.4320

Medical News & Perspectives

Researchers Focus on Recovery in Schizophrenia

M. J. Friedrich

Abstract Full Text

JAMA. 2014;312(1):16-18. doi:10.1001/jama.2014.7450

High Rotavirus Vaccination Rates Continue to Pay Off

Bridget M. Kuehn, MSJ

Abstract Full Text

JAMA. 2014;312(1):18. doi:10.1001/jama.2014.7939

News From the Centers for Disease Control and Prevention

news@JAMA

From JAMA’s Daily News Site

Abstract Full Text

JAMA. 2014;312(1):18. doi:10.1001/jama.2014.7685

Lab Reports

Investigational Drug May Fight Asbestos-Related Cancer

Tracy Hampton, PhD

Abstract Full Text

JAMA. 2014;312(1):19. doi:10.1001/jama.2014.7647

Omega-3 Fatty Acid Derivative May Help Treat Diabetes

Tracy Hampton, PhD

Abstract Full Text

JAMA. 2014;312(1):19. doi:10.1001/jama.2014.7709

Wireless System Transfers Power to Deep-Tissue Microimplants

Tracy Hampton, PhD

Abstract Full Text

JAMA. 2014;312(1):19. doi:10.1001/jama.2014.8060

Circadian Clock Dysregulation Linked to Obesity-Related Diseases

Tracy Hampton, PhD

Abstract Full Text

JAMA. 2014;312(1):19. doi:10.1001/jama.2014.8061

The Art of JAMA

The Statue of Liberty in Frédéric-Auguste Bartholdi’s Studio, Paris: Paul-Joseph-Victor Dargaud

Thomas B. Cole, MD, MPH

Abstract Full Text

JAMA. 2014;312(1):8-9. doi:10.1001/jama.2013.279587

Poetry and Medicine

A Note to His Doctor

Kevin Hadduck

Abstract Full Text

JAMA. 2014;312(1):98. doi:10.1001/jama.2014.970

JAMA Revisited

Bicycling—Pro and Con

Abstract Full Text

JAMA. 2014;312(1):99. doi:10.1001/jama.2013.279579

Comment & Response

Kidney Donation and Risk of ESRD

Arthur J. Matas, MD; Jonas Wadstrom, MD, PhD; Hassan N. Ibrahim, MD

Abstract Full Text

JAMA. 2014;312(1):92-93. doi:10.1001/jama.2014.5515

Kidney Donation and Risk of ESRD

Matthew Niemi, MD; Didier A. Mandelbrot, MD

Abstract Full Text

JAMA. 2014;312(1):92. doi:10.1001/jama.2014.5521

Kidney Donation and Risk of ESRD

Bryce Kiberd, MD; Karthik Tennankore, MD

Abstract Full Text

JAMA. 2014;312(1):93. doi:10.1001/jama.2014.5518

Kidney Donation and Risk of ESRD—Reply

Abimereki D. Muzaale, MD, MPH; Allan B. Massie, PhD, MHS; Dorry L. Segev, MD, PhD

Abstract Full Text

JAMA. 2014;312(1):93-94. doi:10.1001/jama.2014.5524

Outcomes After Kidney Donation

Lainie Friedman Ross, MD, PhD; J. Richard Thistlethwaite Jr, MD, PhD

Abstract Full Text

JAMA. 2014;312(1):94. doi:10.1001/jama.2014.6111

Editorial
Understanding Rare Adverse Outcomes Following Living Kidney Donation
John S. Gill, MD; Marcello Tonelli, MD

Outcomes After Kidney Donation

Allan B. Massie, PhD; Abimereki D. Muzaale, MD, MPH; Dorry L. Segev, MD, PhD

Abstract Full Text

JAMA. 2014;312(1):94-95. doi:10.1001/jama.2014.6120

Editorial
Understanding Rare Adverse Outcomes Following Living Kidney Donation
John S. Gill, MD; Marcello Tonelli, MD

Outcomes After Kidney Donation—Reply

John S. Gill, MD; Marcello Tonelli, MD

Abstract Full Text

JAMA. 2014;312(1):95-96. doi:10.1001/jama.2014.6117

Editorial
Understanding Rare Adverse Outcomes Following Living Kidney Donation
John S. Gill, MD; Marcello Tonelli, MD

Electric Uterine Morcellation

Alexander Melamed, MD, MPH

Abstract Full Text

JAMA. 2014;312(1):96. doi:10.1001/jama.2014.6169

Electric Uterine Morcellation—Reply

Kimberly A. Kho, MD, MPH; Ceana H. Nezhat, MD

Abstract Full Text

JAMA. 2014;312(1):96-97. doi:10.1001/jama.2014.6172

Correction

Incorrect Version of Table

Abstract Full Text

free access

JAMA. 2014;312(1):97. doi:10.1001/jama.2014.7397

Incorrect Age

Abstract Full Text

free access

JAMA. 2014;312(1):97. doi:10.1001/jama.2014.7590

Editorial
Understanding Rare Adverse Outcomes Following Living Kidney Donation
John S. Gill, MD; Marcello Tonelli, MD

May 2023 - July 1883

Decade

Year

Issue

July 2, 2014, Vol 312, No. 1, Pages 1-99

Caring for the Critically Ill Patient

Latest from the USPSTF